Reports Q2 revenue $1.6M, consensus $6.92M. “This quarter unquestionably represents a moment of transformation for Roivant, with the brepocitinib data in DM putting us on a new and exciting trajectory. This is further supported by Immunovant’s remission data in Graves’ disease, and by strong continued execution and progress across the board,” said Matt Gline, CEO of Roivant. “We look forward to sharing more about our progress and next chapter at our investor day in December.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ROIV:
- ROIV Upcoming Earnings Report: What to Expect?
- Vor Bio appoints Sokolove as Chief Medical Officer
- Roivant Sciences price target raised to $25 from $16 at Citi
- Roivant Sciences files automatic mixed securities shelf
- Hold Rating for Roivant Sciences Amid Promising Developments and Competitive Challenges